Bavituximab decreases immunosuppressive myeloid-derived suppressor cells in newly diagnosed glioblastoma patients.

K Ina Ly Leland G K Richardson Mofei Liu Alona Muzikansky Jonathan Cardona Kevin Lou Andrew L Beers Ken Chang James M Brown Xiaoyue Ma David A Reardon Isabel C Arrillaga-Romany Deborah A Forst Justin T Jordan Eudocia Quant Lee Jorg Dietrich Lakshmi Nayak Patrick Yung Wen Ugonma N Chukwueke Anita Giobbie-Hurder Bryan D Choi Tracy T Batchelor Jayashree Kalpathy-Cramer William T Curry Elizabeth R Gerstner

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Bavituximab has activity in newly diagnosed GBM and resulted in on-target depletion of intratumoral immunosuppressive MDSCs. Elevated pre-treatment expression of myeloid-related transcripts in GBM may predict response to bavituximab.

Keyphrases

newly diagnosed
poor prognosis
induced apoptosis
end stage renal disease
ejection fraction
acute myeloid leukemia
bone marrow
peritoneal dialysis
signaling pathway
oxidative stress
immune response
pi k akt
patient reported outcomes